EMA Provides Rapid Feedback on GSK Ebola Vaccine
European Medicines Agency has given 'rapid scientific advice'
For the first time in the current Ebola outbreak, the European Medicines Agency (EMA) has given ‘rapid scientific advice’ using an accelerated procedure to GSK on its development plan for an Ebola vaccine.
Through rapid scientific advice, developers can receive EMA’s expert opinion and advice on topics such as clinical trial design, manufacturing-related questions as well as safety monitoring of medicines. EMA established this procedure to contribute to the global response against Ebola and to help companies speed up the development of vaccines and treatments.
EMA hopes this procedure will help companies to generate the robust data and information needed to assess that treatments and vaccines against Ebola actually work, are acceptably safe and of high quality. It says it will assess any data in a ‘rolling review’, as soon as they become available.
The initial review and any subsequent updates will be shared with healthcare decision-makers in countries affected by the current Ebola outbreak. This will help them to take informed decisions on whether and how they want to use vaccines and medicines in their specific situation.
Read the full release here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
